View Filing Data

Document And Entity Information - USD ($) $ in Millions	12 Months Ended
Document And Entity Information - USD ($) $ in Millions	Dec. 31, 2018	Mar. 13, 2019	Jun. 30, 2018
Document Information [Line Items]
Entity Registrant Name	Diffusion Pharmaceuticals Inc.
Entity Central Index Key	0001053691
Trading Symbol	dffn
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Common Stock, Shares Outstanding (in shares)		3,379,345
Entity Public Float			$ 25.3
Entity Shell Company	false
Document Type	10-K
Document Period End Date	Dec. 31, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	FY
Amendment Flag	false

Consolidated Balance Sheets - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 7,991,172	$ 8,896,468
Prepaid expenses, deposits and other current assets	923,059	769,946
Total current assets	8,914,231	9,666,414
Property and equipment, net	350,281	460,652
Intangible asset	8,639,000	8,639,000
Goodwill	0	6,929,258
Other assets	298,480	450,491
Total assets	18,201,992	26,145,815
Current liabilities:
Current portion of convertible debt		550,000
Accounts payable	198,818	511,956
Accrued expenses and other current liabilities	605,226	1,628,851
Total current liabilities	804,044	2,690,807
Deferred income taxes	1,786,389	2,223,678
Other liabilities		1,386
Total liabilities	2,590,433	4,915,871
Commitments and Contingencies (Note 8)
Convertible preferred stock, $0.001 par value: Series A - No shares authorized, issued or outstanding at December 31, 2018, 13,750,000 shares authorized, 12,376,329 shares issued and 8,306,278 shares outstanding at December 31, 2017	0	0
Stockholders’ Equity:
Common stock, $0.001 par value: 1,000,000,000 shares authorized; 3,376,230 and 967,976 shares issued and outstanding at December 31, 2018 and 2017, respectively	3,377	968
Additional paid-in capital	95,532,881	82,783,865
Accumulated deficit	(79,924,699)	(61,554,889)
Total stockholders' equity	15,611,559	21,229,944
Total liabilities, convertible preferred stock and stockholders' equity	$ 18,201,992	$ 26,145,815

Consolidated Balance Sheets (Parentheticals) - $ / shares	Dec. 31, 2018	Dec. 31, 2017
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	0	13,750,000
Preferred stock, shares issued (in shares)	0	12,376,329
Preferred stock, shares outstanding (in shares)	0	8,306,278
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	1,000,000,000	1,000,000,000
Common stock, shares issued (in shares)	3,376,230	967,976
Common stock, shares outstanding (in shares)	3,376,230	967,976

Consolidated Statements of Operations - USD ($)	12 Months Ended
Consolidated Statements of Operations - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Operating expenses:
Research and development	$ 5,751,940	$ 5,088,621
General and administrative	6,167,177	6,191,845
Goodwill impairment	6,929,258
Depreciation	110,371	67,981
Loss from operations	18,958,746	11,348,447
Other expense (income):
Interest (income) expense, net	(151,647)	48,006
Change in fair value of warrant liability		(22,072,322)
Warrant related expenses		10,225,846
Other financing expenses		2,870,226
Loss from operations before income tax benefit	(18,807,099)	(2,420,203)
Income tax benefit	(437,289)	(1,055,685)
Net loss	(18,369,810)	(1,364,518)
Accretion of Series A cumulative preferred dividends	(85,993)	(1,252,394)
Deemed dividend related to the make-whole provision for the conversion of Series A convertible preferred stock into common stock	(8,167,895)
Net loss attributable to common stockholders	$ (26,623,698)	$ (2,616,912)
Per share information:
Net loss per share of common stock, basic (in dollars per share)	$ (8.21)	$ (3.16)
Net loss per share of common stock, diluted (in dollars per share)	$ (8.21)	$ (29.11)
Weighted average shares outstanding, basic (in shares)	3,242,301	827,575
Weighted average shares outstanding, diluted (in shares)	3,242,301	848,090

Consolidated Statements of Changes in Stockholders' Equity - USD ($)

Preferred Stock [Member]

Series A Preferred Stock [Member]

Common Stock [Member]

Additional Paid-in Capital [Member]

Retained Earnings [Member]

Total

Balance (in shares) at Dec. 31, 2016

689,709

Balance at Dec. 31, 2016

$ 690

$ 69,373,231

$ (60,189,237)

$ 9,184,684

Cumulative effect of change in accounting principle (a) at Dec. 31, 2016

^[1]

1,134

(1,134)

Sale of Series A convertible preferred stock and common stock warrants (in shares)

12,376,329

Sale of Series A convertible preferred stock and common stock warrants

Reclassification of the fair market value of the Series A warrants

13,153,524

$ 13,153,524

Common stock issued for advisory services (in shares)

1,174

Common stock issued for advisory services

$ 1

49,999

$ 50,000

Series A cumulative preferred dividend

(1,252,394)

Reclassification of accrued dividends upon conversion of Series A (in shares)

5,756

Conversion of accrued dividends related to convertible preferred stock

$ 6

190,074

190,080

Conversion of Series A convertible preferred stock to common stock (in shares)

(4,070,051)

271,337

Conversion of Series A convertible preferred stock to common stock

$ 271

(271)

Beneficial conversion feature for accrued interest of convertible debt

28,017

Stock-based compensation expense

1,240,551

Net loss

(1,364,518)

Balance (in shares) at Dec. 31, 2017

8,306,278

967,976

Balance at Dec. 31, 2017

$ 968

82,783,865

(61,554,889)

$ 21,229,944

Common stock issued for advisory services (in shares)

7,792

Common stock issued for advisory services

$ 8

49,992

$ 50,000

Series A cumulative preferred dividend

(85,993)

Conversion of accrued dividends related to convertible preferred stock

Conversion of Series A convertible preferred stock to common stock (in shares)

(8,306,278)

553,752

Conversion of Series A convertible preferred stock to common stock

$ 554

(554)

Stock-based compensation expense

1,221,591

Net loss

(18,369,810)

Balance (in shares) at Dec. 31, 2018

3,376,230

Issuance of common stock to Series A convertible preferred stockholders under make-whole adjustment feature (in shares)

777,895

Issuance of common stock to Series A convertible preferred stockholders under make-whole adjustment feature

$ 778

(778)

Issuance of common stock related to accrued dividends (in shares)

68,815

Issuance of common stock related to accrued dividends

$ 69

1,148,238

1,148,307

Issuance of common stock and warrants, net of issuance costs (in shares)

1,000,000

Issuance of common stock and warrants, net of issuance costs

$ 1,000

10,416,520

10,417,520

Balance at Dec. 31, 2018

$ 3,377

$ 95,532,881

$ (79,924,699)

$ 15,611,559

[1]	In 2017, the Company adopted provisions of ASU 2016-09, Improvements to Employee Share Based Payment Accounting, resulting in a cumulative effect adjustment to Accumulated Deficit and Additional Paid-in Capital for previously unrecognized stock-based compensation expense.

Consolidated Statements of Cash Flow - USD ($)	12 Months Ended
Consolidated Statements of Cash Flow - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Operating activities:
Net loss	$ (18,369,810)	$ (1,364,518)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation, Total	110,371	67,981
Stock-based compensation expense	1,221,591	1,240,551
Common stock issued for advisory services	50,000	50,000
Warrant related expense, change in fair value, and other financing expenses		(8,976,250)
Change in deferred income taxes	(437,289)	(1,055,685)
Goodwill impairment	6,929,258
Non-cash interest expense, net		33,517
Changes in operating assets and liabilities:
Prepaid expenses, deposits and other assets	(1,102)	(664,162)
Accounts payable, accrued expenses and other liabilities	(275,835)	(1,663,789)
Net cash used in operating activities	(10,772,816)	(12,332,355)
Cash flows used in investing activities:
Purchases of property and equipment		(447,823)
Purchases of certificates of deposit		(10,000,000)
Maturities of certificates of deposit		10,000,000
Net cash used in investing activities		(447,823)
Cash flows provided by financing activities:
Proceeds from sale of common stock	10,846,062
Proceeds from the sale of Series A convertible preferred stock and warrants, net		22,129,774
Repayment of convertible debt	(550,000)	(1,880,000)
Payment of offering costs	(428,542)	(125,980)
Net cash provided by financing activities	9,867,520	20,123,794
Net (decrease) increase in cash and cash equivalents	(905,296)	7,343,616
Cash and cash equivalents at beginning of year	8,896,468	1,552,852
Cash and cash equivalents at end of year	7,991,172	8,896,468
Supplemental disclosure of cash flow information:
Cash paid for interest	40,142	112,800
Supplemental disclosure of non-cash investing and financing activities:
Reclassification of accrued dividends related to the issuance of common stock to Series A convertible preferred stock holders	1,148,307
Reclassification of the fair market value of the Series A warrants		13,153,524
Series A cumulative preferred dividends	85,993	1,252,394
Conversion of accrued dividends related to convertible preferred stock		190,080
Offering costs in accounts payable and accrued expenses		$ 146,776

Note 1 - Organization and Description of Business	12 Months Ended
Note 1 - Organization and Description of Business	Dec. 31, 2018
Notes to Financial Statements
Nature of Operations [Text Block]	1. Organization and Description of Business Diffusion Pharmaceuticals Inc. (“Diffusion” or the “Company”), a Delaware corporation, is a clinical stage biotechnology company developing new treatments for life threatening conditions by improving the body’s ability to bring oxygen to the areas where it is needed most. The Company is developing its lead product candidate, transcrocetinate sodium, also known as trans sodium crocetinate (“TSC”), for use in those life threatening conditions in which cellular oxygen deprivation (“hypoxia”) is the basis for significant unmet medical needs. TSC is designed to safely and selectively target and re-oxygenate the micro-environment of hypoxic cells, and can potentially be used in many indications, including oncology and cardiovascular/stroke. In cancer, TSC re-oxygenates treatment-resistant cancerous tissue, making the cancer cells up to three times more susceptible to the therapeutic effects of standard-of-care radiation therapy and chemotherapy. In stroke, TSC helps promote the diffusion of oxygen into those brain cells in which oxygen-deprivation causes neuronal death resulting in patient mortality or morbidity. In addition to the TSC programs, the Company is exploring alternatives regarding how best to capitalize upon our product candidate RES- 529, which may include possible out-licensing and other options. RES- 529 is a novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase 1 clinical trials for age-related macular degeneration and was in preclinical development in oncology, specifically GBM. RES- 529 has shown activity in both in vitro and in vivo glioblastoma animal models and has been demonstrated to be orally bioavailable and capable of crossing the blood brain barrier. On December 13, 2018, the Company effected a 1 -for- 15 reverse split of its common stock. As a result of the reverse stock split, every fifteen shares of common stock outstanding immediately prior to the reverse stock split were reclassified and combined into one share of Common Stock. No fractional shares were issued in connection with the reverse stock split. Stockholders who otherwise would have been entitled to receive fractional shares of common stock had their holdings rounded up to the next whole share. Proportional adjustments were made to the Company’s outstanding warrants, stock options and other equity securities and to the Company’s 2015 Equity Incentive Plan, as amended, to reflect the reverse stock split, in each case, in accordance with the terms thereof. The accompanying consolidated financial statements and these notes give retroactive effect to this reverse stock split.

Note 2 - Liquidity	12 Months Ended
Note 2 - Liquidity	Dec. 31, 2018
Notes to Financial Statements
Liquidity [Text Block]	2. Liquidity The Company has not generated any revenues from product sales and has funded operations primarily from the proceeds of public offerings, convertible debt and convertible preferred stock. Substantial additional financing will be required by the Company to continue to fund its research and development activities. No assurance can be given that any such financing will be available when needed or that the Company’s research and development efforts will be successful. The Company regularly explores alternative means of financing its operations and seeks funding through various sources, including public and private securities offerings, collaborative arrangements with third parties and other strategic alliances and business transactions. On January 22, 2018, the Company closed an underwritten public offering of 1,000,000 shares of the Company’s common stock, par value $0.001 per share (“Common Stock”) and warrants to purchase 1,000,000 shares of Common Stock. At the closing, the Company also issued warrants to purchase an additional 131,375 shares of Common Stock pursuant to the underwriter’s partial exercise of its overallotment option. The shares of Common Stock and warrants were sold at a combined public offering price of $12.00 per share and warrant for total proceeds of approximately $10.8 million. The warrants have an exercise price of $12.00 per share and a term of five years from the date of issuance. In addition, at the closing, the Company issued to designees of the underwriter of the offering warrants to purchase up to 50,000 shares of Common Stock. The underwriter’s warrants have an exercise price of $15.00, a term of five years from the date of issuance and otherwise substantially similar terms to the form of investor warrant. As a result of the offering, all outstanding shares of the Company's Series A convertible preferred stock converted into 1,400,462 shares of Common Stock (including accrued dividends on the Series A convertible preferred stock paid-in-kind and issuance of shares of Common Stock in respect of the “make-whole” adjustment feature thereof). The Company currently does not have any commitments to obtain additional funds and may be unable to obtain sufficient funding in the future on acceptable terms, if at all. If the Company cannot obtain the necessary funding, it will need to delay, scale back or eliminate some or all of its research and development programs or enter into collaborations with third parties to: commercialize potential products or technologies that it might otherwise seek to develop or commercialize independently; consider other various strategic alternatives, including a merger or sale of the Company; or cease operations. If the Company engages in collaborations, it may receive lower consideration upon commercialization of such products than if it had not entered into such arrangements or if it entered into such arrangements at later stages in the product development process. The Company has prepared its financial statements assuming that it will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred net losses since inception and it expects to generate losses from operations for the foreseeable future primarily due to research and development costs for its potential product candidates, which raises substantial doubt about the Company’s ability to continue as a going concern. The Company currently has no sources of revenue and its ability to continue as a going concern is dependent on its ability to raise capital to fund its future business plans. Additionally, volatility in the capital markets and general economic conditions in the United States may be a significant obstacle to raising the required funds. These factors raise substantial doubt about its ability to continue as a going concern. The financial statements included herein do not include any adjustments that might be necessary should the Company be unable to continue as a going concern. If the going concern basis were not appropriate for these financial statements, adjustments would be necessary in the carrying value of assets and liabilities, the reported expenses and the balance sheet classifications used. Operations of the Company are subject to certain risks and uncertainties including various internal and external factors that will affect whether and when the Company’s product candidates become approved drugs and how significant their market share will be, some of which are outside of the Company’s control. The length of time and cost of developing and commercializing these product candidates and/or failure of them at any stage of the drug approval process will materially affect the Company’s financial condition and future operations. The Company believes its cash and cash equivalents as of December 31, 2018 are sufficient to fund operations into July 2019.

Note 3 - Basis of Presentation and Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2018

Notes to Financial Statements

Significant Accounting Policies [Text Block]

Basis of Presentation and Summary of Significant Accounting Policies

Basis of Presentation

The accompanying consolidated financial statements of the Company have been prepared in accordance with US GAAP. Any reference in these notes to applicable guidance is meant to refer to US GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”).

Use of Estimates

The preparation of financial statements in conformity with US GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.

On an ongoing basis, the Company evaluates its estimates using historical experience and other factors, including the current economic environment. Significant items subject to such estimates are assumptions used for purposes of determining stock-based compensation, the fair value of the warrants, the fair value of the convertible notes, and accounting for research and development activities. Management believes its estimates to be reasonable under the circumstances. Actual results could differ significantly from those estimates.

Fair Value of Financial Instruments

The carrying amounts of the Company’s financial instruments, including cash equivalents, accounts payable, and accrued expenses approximate fair value due to the short-term nature of those instruments. As of

December

31,

2017,

the fair value of the Company's outstanding Series B convertible note was approximately

$0.6

million. The fair value of the convertible note was determined using a binomial lattice model that utilizes certain unobservable inputs that fall within Level

of the fair value hierarchy. All amounts outstanding under the Series B convertible note were repaid during the year ended

December 31, 2018.

Concentration of Credit Risk

Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash on deposit with multiple financial institutions, the balances of which frequently exceed federally insured limits.

Cash and Cash Equivalents

The Company considers any highly liquid investments, such as money market funds, with an original maturity of

three

months or less to be cash and cash equivalents.

Property and Equipment

The Company records property and equipment at cost less accumulated depreciation and amortization. Costs of renewals and improvements that extend the useful lives of the assets are capitalized. Maintenance and repairs are expensed as incurred. Depreciation is recognized on a straight-line basis over the estimated useful lives of the assets, which generally range from

years. The Company amortizes leasehold improvements over the shorter of the estimated useful life of the asset or the term of the related lease. Upon retirement or disposition of assets, the costs and related accumulated depreciation and amortization are removed from the accounts with the resulting gains or losses, if any, reflected in results of operations.

Long-Lived Assets

Long-lived assets are reviewed for potential impairment whenever events indicate that the carrying amount of such assets

may

not

be recoverable. The Company does this by comparing the carrying value of the long-lived assets with the estimated future undiscounted cash flows expected to result from the use of the assets, including cash flows from disposition. If it is determined an impairment exists, the asset is written down to its estimated fair value. The Company has

not

recognized any impairment of long-lived assets during the years ended

December 31, 2018

and

2017.

Goodwill and Intangible Assets

Goodwill and intangible assets deemed to have indefinite lives are

not

amortized but rather are tested at least annually for impairment, or when circumstances indicate that the carrying amount of the asset

may

not

be recoverable. If the carrying value of the reporting unit exceeds fair value, goodwill is considered impaired. In

January 2017,

the FASB issued revised guidance that simplifies the test for goodwill impairment, effective for fiscal years beginning after

December 15, 2019,

with early adoption permitted. The Company early adopted this standard in the

third

quarter of

2018.

Under the revised guidance, if a reporting unit’s carrying value exceeds its fair value, an impairment charge will be recorded to reduce the reporting unit to fair value. The Company has a single reporting unit and all goodwill relates to that reporting unit. The Company's RES-

529

intangible asset and goodwill are assessed for impairment annually on

October 1

of the Company’s fiscal year or more frequently if impairment indicators exist. There was

impairment to the Company’s RES-

529

intangible asset recognized during the years ended

December 31, 2018

and

2017.

During the year ended

December 31, 2018,

the Company recorded a non-cash goodwill impairment charge of

$6.9

million (see Note

Research and Development

Major components of research and development costs include internal research and development (such as salaries and related employee benefits, equity-based compensation, supplies and allocated facility costs) and contracted services (research and development activities performed on the Company’s behalf). Costs incurred for research and development are expensed as incurred.

At the end of the reporting period, the Company compares payments made to

third

-party service providers to the estimated progress toward completion of the research or development objectives. Such estimates are subject to change as additional information becomes available. Depending on the timing of payments to the service providers and the progress that the Company estimates has been made as a result of the services provided, the Company

may

record net prepaid or accrued expenses relating to these costs.

Upfront payments made to

third

parties who perform research and development services on the Company’s behalf are expensed as services are rendered.

Patent Costs

Patent costs, including related legal costs, are expensed as incurred and are recorded within general and administrative expenses in the statements of operations.

Income Taxes

As a corporation, the Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. A valuation allowance is provided when it is more likely than

not

that some portion or all of a deferred tax asset will

not

be realized. The Company recognizes the benefit of an uncertain tax position that it has taken or expects to take on its income tax return it files, if such a position is more likely than

not

to be sustained.

Stock-based Compensation

The Company measures employee and nonemployee stock-based awards at grant-date fair value and records compensation expense on a straight-line basis over the vesting period of the award. Stock-based awards issued to non-employees are revalued until the award vests. The Company uses the Black-Scholes option pricing model to value its stock option awards. Estimating the fair value of stock option awards requires management to apply judgment and make estimates, including the volatility of the Company’s common stock, the expected term of the Company’s stock options, the expected dividend yield and the fair value of the Company’s common stock on the measurement date. As a result, if factors change and management uses different assumptions, stock-based compensation expense could be materially different for future awards.

The expected term of stock options was estimated using the “simplified method” for employee options as the Company has

historical information to develop reasonable expectations about future exercise patterns and post vesting employment termination behavior for its stock option grants. The simplified method is based on the average of the vesting tranches and the contractual life of each grant. For options granted to non-employees, the Company uses the remaining contractual life. For stock price volatility, the Company uses comparable public companies as a basis for its expected volatility to calculate the fair value of option grants. The Company assumes

dividend yield because dividends are

not

expected to be paid in the near future, which is consistent with the Company’s history of

not

paying dividends. The risk-free interest rate is based on U.S. Treasury notes with a term approximating the expected life of the option. The Company

longer estimates forfeitures and accounts for forfeitures in the periods they occur.

Net Loss Per Share

Basic loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during each period. For purposes of calculating diluted loss per common share, the denominator includes both the weighted average common shares outstanding and the number of common stock equivalents if the inclusion of such common stock equivalents would be dilutive. Dilutive common stock equivalents potentially include warrants, stock options and restricted stock awards using the treasury stock method and convertible debt using the “if-converted” method. The diluted loss per common share calculation is further affected by an add-back of change in fair value of warrant liability to the numerator under the assumption that the change in fair value of warrant liability would

not

have been incurred if the warrants had been converted into common stock.

	Year ended December 31,
	2018			2017
Basic net loss per common share calculation:
Net loss	$	(18,369,810	)	$	(1,364,518	)
Accretion of Series A cumulative preferred dividends		(85,993	)		(1,252,394	)
Deemed dividend related to the make-whole provision for the conversion of Series A convertible preferred stock into common stock		(8,167,895	)		—
Net loss attributable to common stockholders	$	(26,623,698	)	$	(2,616,912	)

Weighted average shares outstanding, basic		3,242,301			827,575
Net loss per share of common, basic	$	(8.21	)	$	(3.16	)
Diluted net loss per common share calculation:
Net loss attributable to common stockholders		(26,623,698	)		(2,616,912	)
Change in fair value of warrant liability		—			(22,072,322	)
Diluted net loss		(26,623,698	)		(24,689,234	)
Weighted average common shares outstanding, basic		3,242,301			827,575
Common stock equivalents arising from warrants		—			20,515
Common stock equivalents		3,242,301			848,090
Net loss per share of common stock, diluted	$	(8.21	)	$	(29.11	)

The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted average shares outstanding, as they would be anti-dilutive:

	December 31,
	2018		2017
Convertible debt		—		14,292
Common stock warrants		2,087,012		29,848
Convertible preferred stock		—		553,752
Stock options		203,736		170,461
Unvested restricted stock awards		—		204
		2,290,748		768,557

Amounts in the table reflect the common stock equivalents of the noted instruments.

Comprehensive Loss

The Company has

items of comprehensive income or loss other than net loss.

Recently Issued But

Not

Yet Adopted Accounting Pronouncements

August 2018,

the FASB issued ASU

2018

13,

Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurements,

which changes the fair value measurement disclosure requirements of ASC

820.

The goal of the ASU is to improve the effectiveness of ASC

820's

disclosure requirements by providing users of the financial statements with better information about assets and liabilities measured at fair value in the financial statements and notes thereto. The guidance is applicable to public business entities for fiscal years beginning after

December 15, 2019

and interim periods within those years. The Company is currently evaluating the potential impact of the adoption of this standard on its related disclosures.

July 2017,

the FASB issued ASU

2017

11,

Earnings Per Share (Topic

260

); Distinguishing Liabilities from Equity (Topic

480

); Derivatives and Hedging (Topic

815

): (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception.

The

first

part of this update addresses the complexity of accounting for certain financial instruments with down round features and the

second

part addresses the complexity of distinguishing liabilities from equity. The guidance is applicable to public business entities for fiscal years beginning after

December 15, 2018

and interim periods within those years. The Company is currently evaluating the potential impact of the adoption of this standard on its consolidated results of operations, financial position and cash flows and related disclosures.

February 2016,

the FASB issued ASU

2016

02,

Leases (Topic

842

Under the new guidance

lessees are required to record a right-of-use (ROU) asset and a lease liability for all leases with a term greater than

months, measured on a discounted basis. Leases with a term of

months or less will be accounted for similar to existing guidance for operating leases. ASC

842

will be effective for the Company on

January 1, 2019,

and the Company expects to apply the practical expedients allowed by the standard, mainly related to the reassessment of expired or existing leases. See Note

for details of the Company's current lease arrangement. Although management continues to evaluate the effect to the Company's Consolidated Financial Statements and disclosures, management currently estimates total assets and liabilities will increase approximately

$0.3

million to

$0.4

million upon adoption. Management does

not

expect a material impact to the Company’s Consolidated Statements of Operations or Consolidated Statements of Cash Flows.

Recently Adopted Accounting Pronouncements

January 2017,

the FASB issued ASU

2017

04,

Intangibles-Goodwill and Other (Topic

350

)

which simplifies the accounting for goodwill impairments by eliminating step

from the goodwill impairment test. Instead, if the carrying amount of a reporting unit exceeds its fair value, an impairment loss shall be recognized in an amount equal to that excess, limited to the total amount of goodwill allocated to that reporting unit. The standard will be effective for fiscal years beginning after

December 15, 2019,

including interim periods within such fiscal years. Early adoption is allowed for all entities as of

January 1, 2017,

for annual and any interim impairment tests occurring on or after

January 1, 2017.

The Company early adopted this standard in the

third

quarter of

2018.

See Note

for further discussion of the Company's intangible assets, including goodwill.

March

2016,

the FASB issued ASU

2016

09,

Compensation – Improvements to Employee Share-Based Payment Accounting

, which simplifies several aspects of the accounting for employee share-based payment transactions including the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification in the statement of cash flows. The guidance is applicable to public business entities for fiscal years beginning after

December 15, 2016

and interim periods within those years. The Company adopted this standard in

2017

by electing to account for forfeitures in the period that they occur. Under ASU

2016

09,

accounting changes adopted using the modified retrospective method must be calculated as of the beginning of the period adopted and reported as a cumulative-effect adjustment. As a result, the Company recognized cumulative-effect adjustment of approximately

$1,000

January 1, 2017.

Note 4 - Property and Equipment

12 Months Ended

Dec. 31, 2018

Notes to Financial Statements

Property, Plant and Equipment Disclosure [Text Block]

Property and Equipment

Property and equipment consists of the following:

	December 31,
	2018			2017
Laboratory equipment	$	182,357		$	182,357
Furniture and office equipment		155,113			155,113
Leasehold improvements		430,000			430,000
Total property and equipment		767,470			767,470
Less: accumulated depreciation		(417,189	)		(306,818	)
Property and equipment, net	$	350,281		$	460,652

Depreciation expense was approximately

$0.1

million and

$68,000

for the years ended

December 31, 2018

and

2017,

respectively.

Note 5 - Goodwill and Intangible Assets	12 Months Ended
Note 5 - Goodwill and Intangible Assets	Dec. 31, 2018
Notes to Financial Statements
Goodwill and Intangible Assets Disclosure [Text Block]	5. Goodwill and Intangible Assets Goodwill is the excess of the cost of an acquired entity over the net amounts assigned to tangible and intangible assets acquired and liabilities assumed. The Company applies ASC 350 “ Goodwill and Other Intangible Assets ,” which requires testing goodwill for impairment on an annual basis. The Company evaluates goodwill on a consolidated basis as the Company is organized as a single reporting unit. The Company completes its annual impairment test on October 1 each year, or more frequently if triggering events indicate a possible impairment. The Company considers certain triggering events when evaluating whether an interim goodwill impairment analysis is warranted. Among these would be a significant long-term decrease in the market capitalization of the Company. The Company’s market capitalization was below the carrying value of equity throughout the third quarter of 2018 and as a result, management concluded that the carrying value of goodwill may not be recoverable and that a triggering event requiring an interim assessment of goodwill impairment had occurred during the three months ended September 30, 2018. Management performed the goodwill impairment assessment using a market approach to estimate the fair value of the Company using the Company's market capitalization. This fair value was derived by multiplying the Company's shares outstanding by the average daily close prices of the Company's stock during the third quarter of 2018. The carrying value of the Company's net equity exceeded its fair value, and accordingly, the Company recognized a $4.2 million non-cash impairment charge to goodwill that reduced the carrying value to fair value. During the fourth quarter of 2018, this downward trend of the Company's market capitalization continued, and the Company performed another goodwill impairment assessment using a market approach to estimate the fair value of the Company. This fair value was derived by multiplying the Company's shares outstanding by the average daily close prices of the Company's stock during the fourth quarter. The carrying value of the Company's net equity exceeded its fair value, and accordingly, the Company recognized an additional $2.7 million non-cash impairment charge to goodwill. As a result of these impairment charges, the Company has no goodwill remaining on its consolidated balance sheet as of December 31, 2018. The Company has an indefinite-lived In-Process Research and Development Asset (IPR&D) called RES- 529, which has a balance of $8.6 million at both December 31, 2018 and December 31, 2017. RES- 529 is a PI3K/Akt/mTOR pathway inhibitor in preclinical development for oncology. There was no impairment to the Company’s RES- 529 intangible asset recognized during the years ended December 31, 2018 or 2017.

Note 6 - Accrued Expenses and Other Current Liabilities

12 Months Ended

Dec. 31, 2018

Notes to Financial Statements

Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]

Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consist of the following:

	December 31,
	2018		2017
Accrued interest payable	$	—	$	37,415
Accrued Series A convertible preferred stock dividends		—		1,062,314
Accrued payroll and payroll related expenses		409,889		312,221
Accrued professional fees		69,231		122,711
Accrued clinical studies expenses		34,000		63,350
Other		92,106		30,840
Total	$	605,226	$	1,628,851

Note 7 - Convertible Debt

12 Months Ended

Dec. 31, 2018

Notes to Financial Statements

Debt Disclosure [Text Block]

Convertible Debt

The components of debt outstanding at

December

31,

2017

was as follows:

	December 31, 2017
Series B convertible notes		550,000
Less current portion		(550,000	)
Long-term debt, net of current portion	$	—

Upon maturity of the Series B convertible debt during the

second

quarter of

2018,

the Company repaid the outstanding principal and interest of approximately

$0.6

million and

$40,000,

respectively. As such, the Company does

not

have any debt outstanding as of

December 31, 2018.

For the years ended

December 31, 2018

and

2017,

the Company recognized interest expense of approximately

$3,000

and

$0.1

million, respectively in connection with its convertible debt instruments. Accrued interest was

$37,000

as of

December 31, 2017.

Note 8 - Commitments and Contingencies

12 Months Ended

Dec. 31, 2018

Notes to Financial Statements

Commitments and Contingencies Disclosure [Text Block]

Commitments and Contingencies

Office Space Lease Commitment

The Company leases office and laboratory facilities in Charlottesville, Virginia. Rent expense related to the Company's operating lease for both the years ended

December

31,

2018

and

2017

was approximately

$0.1

million. Future minimum rental payments under the Company's non-cancelable operating lease at

December

31,

2018

were as follows:

	Rental Commitments
2019	$	114,409
2020		116,464
2021		118,519
2022		39,735
Total	$	389,127

Arrangements with Clinical Research Organization

The Company has various agreements with contract research organizations (“CROs”) to provide clinical trial services for individual studies and projects by executing individual work orders governed by Master Service Arrangements (“MSAs”). The MSAs and associated work orders are designed such that quarterly payments are to be made in advance of the work to be performed. The Company recognized research and development expenses related to these MSAs of

$1.6

million and

$1.0

million during the years ended

December 31, 2018

and

2017,

respectively. As of

December

31,

2018,

there was

$0.8

million of prepaid research and development costs that are estimated to be recognized during fiscal

2019.

Legal Proceedings

August 7, 2014,

a complaint was filed in the Superior Court of Los Angeles County, California by Paul Feller, the Company’s former Chief Executive Officer under the caption

Paul Feller v. RestorGenex Corporation, Pro Sports & Entertainment, Inc., ProElite, Inc. and Stratus Media Group, GmbH

(Case

No.

BC553996

). The complaint asserts various causes of action, including, among other things, promissory fraud, negligent misrepresentation, breach of contract, breach of employment agreement, breach of the covenant of good faith and fair dealing, violations of the California Labor Code and common counts. The plaintiff is seeking, among other things, compensatory damages in an undetermined amount, punitive damages, accrued interest and an award of attorneys’ fees and costs. On

December 30, 2014,

the Company filed a petition to compel arbitration and a motion to stay the action. On

April 1, 2015,

the plaintiff filed a petition in opposition to the Company’s petition to compel arbitration and a motion to stay the action. After a hearing for the petition and motion on

April 14, 2015,

the Court granted the Company’s petition to compel arbitration and a motion to stay the action. On

January 8, 2016,

the plaintiff filed an arbitration demand with the American Arbitration Association. On

November 19, 2018

at an Order to Show Cause Re Dismissal Hearing, the Court found sufficient grounds

not

to dismiss the case, and an arbitration hearing has been scheduled for

November 2019.

The Company believes this matter is without merit and intends to defend the arbitration vigorously. Because this matter is in an early stage, the Company is unable to predict its outcome and the possible loss or range of loss, if any, associated with its resolution or any potential effect the matter

may

have on the Company’s financial position. Depending on the outcome or resolution of this matter, it could have a material effect on the Company’s financial position.

Note 9 - Convertible Preferred Stock, Stockholders' Equity and Common Stock Warrants

12 Months Ended

Dec. 31, 2018

Notes to Financial Statements

Stockholders' Equity Note Disclosure [Text Block]

Convertible Preferred Stock, Stockholders’ Equity and Common Stock Warrants

2018

Common Stock Offering

January 2018,

the Company entered into an Underwriting Agreement (the “Agreement”) pursuant to which it issued

1,000,000

shares of Common Stock and warrants to purchase

1,000,000

shares of Common Stock with an initial exercise price of

$12.00

per share for cash proceeds of

$10.8

million. In addition, as compensation for its services, the Company granted to the underwriter in the transaction an option (the “Over-Allotment Option”) to purchase, in the aggregate,

150,000

shares of Common Stock (the “Option Shares”) and warrants to purchase up to

150,000

shares of Common Stock (the “Option Warrants”). The underwriter exercised its right to purchase a portion of the Option Warrants and received an additional

131,375

warrants to purchase Common Stock with an initial exercise price

$12.00

per share.

In addition, at the closing, the Company issued to designees of the underwriter warrants to purchase up to

50,000

shares of Common Stock. The underwriter’s warrants have an exercise price of

$15.00

per share, a term of

five

years from the date of issuance and otherwise substantially similar terms to the form of the investor warrant.

During its evaluation of equity classification for the Common Stock warrants, the Company considered the conditions as prescribed within ASC

815

40,

Derivatives and Hedging, Contracts in an Entity’s own Equity

(“ASC

815

40”

). The conditions within ASC

815

are

not

subject to a probability assessment. The warrants do

not

fall under the liability criteria within ASC

480

Distinguishing Liabilities from Equity

as they are

not

puttable and do

not

represent an instrument that has a redeemable underlying security. The warrants do meet the definition of a derivative instrument under ASC

815,

but are eligible for the scope exception as they are indexed to the Company’s own stock and would be classified in permanent equity if freestanding.

As a result of the Company's Common Stock offering in

January 2018,

all outstanding shares of the Company's Series A convertible preferred stock (discussed below) converted into

1,400,462

shares of Common Stock of which (i)

553,752

shares were issued for the automatic conversion of Series A convertible preferred stock (ii)

68,815

shares were issued upon settlement of accrued dividends and (iii)

777,895

shares were issued for the settlement of the “make-whole” adjustment feature. A deemed dividend of

$8.2

million was recognized for the value of the common shares issued for the settlement of the make-whole adjustment feature.

Series A Convertible Preferred Stock

March 2017,

the Company completed a

$25.0

million private placement of its securities in which the Company offered and sold units consisting of

one

share of the Company’s Series A convertible preferred stock and a warrant to purchase

one

share of Common Stock for each share of Series A convertible preferred stock purchased in the private placement (the

“2017

Private Placement”). Each share of Series A convertible preferred stock entitled the holder to an

8.0%

cumulative dividend payable in shares of Common Stock. The holders, at their option, were able to convert each share of Series A convertible preferred stock into

one

share of the Company’s Common Stock based on the initial conversion price of

$30.30

per share, subject to adjustment. Each warrant entitles the holder to purchase

one

share of Common Stock at an initial exercise price of

$33.30,

subject to adjustment and expires on the

fifth

anniversary of their original issuance date.

The Company sold

12,376,329

units in the

2017

Private Placement and received approximately

$22.1

million in aggregate net cash proceeds, after deducting commissions and other expenses of approximately

$2.9

million. In addition, as compensation for its services, the Company granted to its placement agent in the

2017

Private Placement warrants to purchase an aggregate of

78,637

shares of Common Stock at an initial exercise price of

$33.30

per share, which expire on the

fifth

anniversary of their original issuance date.

During its evaluation of equity classification for the common stock warrants, the Company considered the conditions as prescribed within ASC

815

40.

The conditions within ASC

815

are

not

subject to a probability assessment. As the Company was obligated to issue a variable number of shares to settle the cumulative dividends on the Series A convertible preferred stock, the Company could

not

assert that there would be sufficient authorized shares available to settle the warrants issued in connection with the Series A offering. Accordingly, these warrants were classified as liabilities. In

November 2017

the Company effected an amendment to its Certificate of Incorporation to permit the Company to pay dividends on the Company’s Series A Convertible Preferred Stock in either cash or shares of the Company’s Common Stock, which was approved by the stockholders. As a result of this amendment, the warrants were reclassified on the consolidated balance sheet from liabilities to stockholders’ equity in the

fourth

quarter of

2017.

As the fair value of the warrants upon their issuance was in excess of the proceeds of the

2017

Private Placement, there were

proceeds allocated to the Series A convertible preferred stock. The excess fair value of the warrants over the gross proceeds of the

2017

Private Placement and the fair value of the warrants granted to its placement agent was

$10.2

million in the aggregate and were recorded as warrant related expenses in the Company's consolidated statement of operations for the year ended

December

31,

2017.

In contemplation of completing the

2017

Private Placement, pursuant to the Company’s Certificate of Incorporation, on

March 13, 2017,

the Company adopted the Certificate of Designations of Preferences, Rights and Limitations of the Series A Convertible Preferred Stock of the Company, authorizing

13,750,000

shares of Series A Convertible Preferred Stock for issuance. Upon the mandatory conversion of all of the shares of Series A Convertible Preferred Stock into our Common Stock during

2018,

shares of Series A Convertible Preferred Stock remained authorized, issued or outstanding.

Common Stock

In addition to the above offerings of Common Stock, during the years ended

December 31, 2018

and

2017,

respectively, the Company issued

7,792

and

1,174

shares, respectively, for advisory services. The Company did

not

purchase or retire any shares of its Common Stock during the years ended

December 31, 2018

and

2017.

Common Stock Warrants

As of

December

31,

2018,

the Company had the following warrants outstanding to acquire shares of its common stock:

	Outstanding		Range of exercise price per share			Expiration dates
Common stock warrants issued prior to 2016		1,767	$562.50	-	$735.00	2019
Common stock warrants issued in 2017 related to Series A convertible preferred stock offering		903,870		$33.30		March 2022
Common stock warrants issued in 2018 related to the common stock offering		1,181,375	$12.00	-	$15.00	January 2023
		2,087,012

During the years ended

December

31,

2018

and

2017,

28,123

and

867

warrants issued prior to

2016

expired, respectively.

Note 10 - Stock-based Compensation

12 Months Ended

Dec. 31, 2018

Notes to Financial Statements

Disclosure of Compensation Related Costs, Share-based Payments [Text Block]

10.

Stock-Based Compensation

2015

Equity Plan

The

2015

Equity Incentive Plan of the Company, as amended in

July 2016,

currently allows for the issuance of up to a maximum of

33,333

shares of common stock in connection with the grant of stock-based awards, including stock options, restricted stock, restricted stock units, stock appreciation rights and other types of awards as deemed appropriate,

not

including shares subject to awards assumed in connection with certain transactions. As of

December

31,

2018,

there were

1,814

shares of Common Stock available for future issuance under the

2015

Equity Incentive Plan. In addition, beginning on

January 1, 2017,

on each

January 1

through the term of the plan, up to

4.0%

of the total shares of the Company’s common stock outstanding as of

December 31

will be added to the plan reserve, unless a lesser amount is stipulated by the Compensation Committee of the Company’s Board of Directors. On

January 1, 2019,

the maximum number of shares of the

2015

Equity Incentive Plan increased by

135,049

shares, or

4.0%

of the total shares of the Company’s common stock outstanding at

December

31,

2018.

The Company recorded stock-based compensation expense in the following expense categories of its consolidated statements of operations for the periods indicated:

	Year ended December 31,
	2018		2017
Research and development	$	62,161	$	674,643
General and administrative		1,159,430		716,425
Total stock-based compensation expense	$	1,221,591	$	1,391,068

The following table summarizes the activity related to all stock option grants to employees and non-employees:

	Number of Options			Weighted average exercise price per share		Weighted average remaining contractual life (in years)		Aggregate Intrinsic Value
Balance at January 1, 2017		147,214		$	121.37
Granted		23,345			36.92
Expired		(98	)		225.00
Balance at January 1, 2018		170,461		$	109.74		7.13	$	4,746
Granted		44,005			15.37
Forfeited		(10,583	)		131.25
Expired		(147	)		256.50
Outstanding at December 31, 2018		203,736		$	88.14		6.70	$	143
Exercisable at December 31, 2018		167,585		$	101.69		6.25	$	143
Vested and expected to vest at December 31, 2018		203,736		$	88.14		6.70	$	143

Generally, the options have a

ten

(

) year contractual term and vest in equal monthly installments over

three

(

) years.

Non-employee Stock Options

Non-employee options are remeasured to fair value each period through operations using a Black-Scholes option-pricing model until the options vest. There were

options granted to non-employees during the year ended

December 31, 2018

and there were

626

stock options granted to non-employees during the year ended

December

31,

2017.

The total fair value of non-employee stock options vested during the years ended

December

31,

2018

and

2017

was approximately

$4,000

and

$90,000,

respectively. At

December

31,

2018,

there was less than

$1,000

of unrecognized compensation cost related to

219

unvested stock options and subject to re-measurement until vested. The total unrecognized compensation expense will be recognized as expense over a weighted-average period of

1.16

years.

Employee Stock Options

The weighted average grant date fair value of stock option awards granted to employees was

$12.63

and

$30.43

during the years ended

December

31,

2018

and

2017,

respectively. The total fair value of options vested during the years ended

December

31,

2018

and

2017

were

$1.2

million and

$1.1

million, respectively.

options were exercised during any of the periods presented. At

December

31,

2018,

there was

$0.6

million of unrecognized compensation cost related to unvested options that will be recognized as expense over a weighted-average period of

1.4

years.

The grant date fair value of employee stock options is determined using the Black-Scholes model. The following assumptions were used during the years ended

December

31,

2018

and

2017:

	2018			2017
Expected term (in years)	5.27	—	5.66	5.27	—	6.00
Risk-free interest rate	2.3%	—	2.8%	1.8%	—	2.4%
Expected volatility	113.6%	—	115.0%	109.8%	—	136.7%
Dividend yield	—	—	—	—	—	—

Restricted Stock Awards

As of

December

31,

2018,

there were

unvested shares of restricted stock. During the year ended

December

31,

2018

and

2017,

204

and

409

shares vested, respectively. The fair value as of the respective vesting dates of the restricted stock awards was

$6,000

and

$12,000

for

2018

and

2017,

respectively. There were

restricted stock awards granted in

2018

2017.

Note 11 - Defined Contribution Retirement Plan	12 Months Ended
Note 11 - Defined Contribution Retirement Plan	Dec. 31, 2018
Notes to Financial Statements
Pension and Other Postretirement Benefits Disclosure [Text Block]	11. Defined Contribution Retirement Plan The Company has established a 401 (k) defined contribution plan (the 401 (k) Plan) that covers all employees who qualify under the terms of the plan. Eligible employees may elect to contribute to the 401 (k) Plan up to 90% of their compensation, limited by the IRS-imposed maximum. The Company provides a safe harbor match with a maximum amount of 4% of the participant’s compensation. The Company made matching contributions under the 401 (k) Plan of approximately $68,000 and $49,000 for the years ended December 31, 2018 and 2017, respectively.

Note 12 - Income Taxes

12 Months Ended

Dec. 31, 2018

Notes to Financial Statements

Income Tax Disclosure [Text Block]

12.

Income Taxes

Deferred tax assets and liabilities are determined based on the differences between the financial statement carrying amounts and tax bases of assets and liabilities using enacted tax rates in effect for years in which differences are expected to reverse.

Significant components of the Company's deferred tax assets for federal income taxes consisted of the following:

Deferred tax assets	December 31, 2018			December 31, 2017
Net operating loss carryforwards	$	5,875,074		$	5,310,628
Stock option compensation		2,456,410			2,141,973
Orphan Drug credits		2,847,803			2,537,039
Capitalized start-up costs and other		7,349,092			5,247,468
Valuation allowance		(18,091,090	)		(15,237,108	)
Net deferred tax asset	$	437,289

Deferred tax liabilities
Intangible assets		(2,223,678	)		(2,223,678	)
Net deferred tax liability	$	(1,786,389	)	$	(2,223,678	)

The Company does

not

have unrecognized tax benefits as of

December

31,

2018

December 31, 2017.

The Company recognizes interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense.

The Company had net operating loss carryforwards (“NOL”) for federal and state income tax purposes at

December

31,

2018

of approximately:

Combined NOL Carryforwards:	December 31, 2018
Federal	$	22,819,972
State		22,845,568

The net operating loss carryforwards generated prior to

2017

begin expiring in

2034

for both federal and state income tax purposes. Those generated in

2018

and into the future now have an indefinite life. In

January 2016,

the Company increased the number of shares outstanding resulting in a change of ownership, under the provisions of Internal Revenue Code section

382

and similar state provisions. Stock issuances in

2018

and

2017

might have also resulted in changes of ownership. These provisions limit the Company's ability to utilize these net operating loss carryforwards to offset future income. The amounts above reflect the amount of NOLs that the Company expects to be able to utilize as a result of the limitation. Excluding the deferred tax asset associated with the net operating loss with unlimited carryforward, the Company recorded a valuation allowance for the remaining deferred tax assets as of

December 31, 2018,

because of the uncertainty of their realization.

A reconciliation of income tax benefit at the statutory federal income tax rate and income taxes as reflected in the financial statements is as follows:

Rate reconciliation:	December 31, 2018			December 31, 2017
Federal tax benefit at statutory rate		(21.0	)%		(34.0	)%
State tax, net of Federal benefit		(2.9	)%		(16.3	)%
Change in fair value of warrant		—	%		(126.1	)%
Change in tax rate		—	%		205.5	%
Goodwill impairment		7.7	%		—	%
Orphan drug credit		(1.3	)%		(36.0	)%
Change in valuation allowance		15.2	%		(38.8	)%
Stock compensation		—	%		1.2	%
Other		—	%		1.0	%
Total provision		(2.3	)%		(43.5	)%

The Company files income tax returns in the U.S. federal jurisdiction and various state jurisdictions. The Company’s

2015

2017

tax years remain open and subject to examination; carryforward amounts from the

2014

year remain subject to adjustment.

December 22, 2017

the President of the United States signed into law the Tax Cuts and Jobs Act (“The

2017

Tax Act”), which resulted in significant changes from previous tax law. The

2017

Tax Act required the Company to revalue its deferred tax assets and liabilities to the new rate of

21%.

As a result of the change, the Company recorded a tax benefit of

$1.1

million for the year ended

December 31, 2017.

The

2017

Tax Act also changed the net operating loss carryforwards’ period such that all net operating losses generated in

2018

and into the future now have an indefinite life. As a result of the change in net operating loss carryforward period, during the year ended

December 31, 2018,

the Company recognized an income tax benefit of

$0.4

million to reflect the adjustment allowed by the

2017

Tax Act to utilize indefinite deferred tax liabilities as a source of income against indefinite lived portions of the Company’s deferred tax assets.

Note 13 - Fair Value Measurements

12 Months Ended

Dec. 31, 2018

Notes to Financial Statements

Fair Value Disclosures [Text Block]

13.

Fair Value Measurements

Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in

one

of the following

three

levels of the fair value hierarchy, of which the

first

two

are considered observable and the last is considered unobservable:

●	Level 1—Quoted prices in active markets for identical assets or liabilities.

●

Level

2—Observable

inputs (other than Level

quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are

not

active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.

●	Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.

The asset’s or liability’s fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.

The reconciliation of the common stock warrant liability measured at fair value on a recurring basis using significant unobservable inputs (Level

) is as follows:

	Common Stock Warrant Liability
Balance at January 1, 2017	$	—
Issued in connection with the Series A convertible preferred stock		35,225,846
Change in fair value		(22,072,322	)
Reclassification of Series A warrants to additional paid in capital		(13,153,524	)
Balance at December 31, 2017	$	—

The common stock warrants issued in connection with the Series A convertible preferred stock were previously classified as liabilities on the Company's consolidated balance sheet, and were marked-to-market each reporting period with the change in fair value recorded as either income or expense in the accompanying consolidated statements of operations until the warrants were exercised, expired or other facts and circumstances lead the liability to be reclassified to stockholders’ equity. In

November 2017,

the Company effected an amendment to its Certificate of Incorporation to permit the Company to pay dividends on the Company’s Series A Convertible Preferred Stock in either cash or shares of the Company’s Common Stock. As a result of this amendment, the warrants were reclassified on the consolidated balance sheet from liabilities to stockholders’ equity in the

fourth

quarter of

2017.

The fair value of the warrant liability was estimated using the Black-Scholes model and assumptions used to value the warrant liability as of

November 1, 2017,

which was the date of the reclassification, were as follows:

Stock price	$	21.60
Exercise price	$	33.30
Expected term (in years)		4.38
Risk-free interest rate		1.9	%
Expected volatility		104.1	%
Dividend yield		—

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Note 14 - Related Party Transactions	12 Months Ended
Note 14 - Related Party Transactions	Dec. 31, 2018
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	14. Related Party Transactions The Company’s Director of Information Technologies is the son of the Chief Executive Officer and he has held that position since December 2014.

Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2018

Accounting Policies [Abstract]

Basis of Accounting, Policy [Policy Text Block]

Basis of Presentation

Use of Estimates, Policy [Policy Text Block]

Use of Estimates

Fair Value of Financial Instruments, Policy [Policy Text Block]

Fair Value of Financial Instruments

December

31,

2017,

the fair value of the Company's outstanding Series B convertible note was approximately

$0.6

million. The fair value of the convertible note was determined using a binomial lattice model that utilizes certain unobservable inputs that fall within Level

of the fair value hierarchy. All amounts outstanding under the Series B convertible note were repaid during the year ended

December 31, 2018.

Concentration Risk, Credit Risk, Policy [Policy Text Block]

Concentration of Credit Risk

Cash and Cash Equivalents, Policy [Policy Text Block]

Cash and Cash Equivalents

The Company considers any highly liquid investments, such as money market funds, with an original maturity of

three

months or less to be cash and cash equivalents.

Property, Plant and Equipment, Policy [Policy Text Block]

Property and Equipment

Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]

Long-Lived Assets

Long-lived assets are reviewed for potential impairment whenever events indicate that the carrying amount of such assets

may

not

recognized any impairment of long-lived assets during the years ended

December 31, 2018

and

2017.

Goodwill and Intangible Assets, Policy [Policy Text Block]

Goodwill and Intangible Assets

Goodwill and intangible assets deemed to have indefinite lives are

not

amortized but rather are tested at least annually for impairment, or when circumstances indicate that the carrying amount of the asset

may

not

be recoverable. If the carrying value of the reporting unit exceeds fair value, goodwill is considered impaired. In

January 2017,

the FASB issued revised guidance that simplifies the test for goodwill impairment, effective for fiscal years beginning after

December 15, 2019,

with early adoption permitted. The Company early adopted this standard in the

third

quarter of

2018.

529

intangible asset and goodwill are assessed for impairment annually on

October 1

of the Company’s fiscal year or more frequently if impairment indicators exist. There was

impairment to the Company’s RES-

529

intangible asset recognized during the years ended

December 31, 2018

and

2017.

During the year ended

December 31, 2018,

the Company recorded a non-cash goodwill impairment charge of

$6.9

million (see Note

Research and Development Expense, Policy [Policy Text Block]

Research and Development

At the end of the reporting period, the Company compares payments made to

third

may

record net prepaid or accrued expenses relating to these costs.

Upfront payments made to

third

parties who perform research and development services on the Company’s behalf are expensed as services are rendered.

Legal Costs, Policy [Policy Text Block]

Patent Costs

Patent costs, including related legal costs, are expensed as incurred and are recorded within general and administrative expenses in the statements of operations.

Income Tax, Policy [Policy Text Block]

Income Taxes

not

that some portion or all of a deferred tax asset will

not

be realized. The Company recognizes the benefit of an uncertain tax position that it has taken or expects to take on its income tax return it files, if such a position is more likely than

not

to be sustained.

Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]

Stock-based Compensation

The expected term of stock options was estimated using the “simplified method” for employee options as the Company has

dividend yield because dividends are

not

expected to be paid in the near future, which is consistent with the Company’s history of

not

paying dividends. The risk-free interest rate is based on U.S. Treasury notes with a term approximating the expected life of the option. The Company

longer estimates forfeitures and accounts for forfeitures in the periods they occur.

Earnings Per Share, Policy [Policy Text Block]

Net Loss Per Share

not

have been incurred if the warrants had been converted into common stock.

	Year ended December 31,
	2018			2017
Basic net loss per common share calculation:
Net loss	$	(18,369,810	)	$	(1,364,518	)
Accretion of Series A cumulative preferred dividends		(85,993	)		(1,252,394	)
Deemed dividend related to the make-whole provision for the conversion of Series A convertible preferred stock into common stock		(8,167,895	)		—
Net loss attributable to common stockholders	$	(26,623,698	)	$	(2,616,912	)

Weighted average shares outstanding, basic		3,242,301			827,575
Net loss per share of common, basic	$	(8.21	)	$	(3.16	)
Diluted net loss per common share calculation:
Net loss attributable to common stockholders		(26,623,698	)		(2,616,912	)
Change in fair value of warrant liability		—			(22,072,322	)
Diluted net loss		(26,623,698	)		(24,689,234	)
Weighted average common shares outstanding, basic		3,242,301			827,575
Common stock equivalents arising from warrants		—			20,515
Common stock equivalents		3,242,301			848,090
Net loss per share of common stock, diluted	$	(8.21	)	$	(29.11	)

The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted average shares outstanding, as they would be anti-dilutive:

	December 31,
	2018		2017
Convertible debt		—		14,292
Common stock warrants		2,087,012		29,848
Convertible preferred stock		—		553,752
Stock options		214,319		170,461
Unvested restricted stock awards		—		204
		2,301,331		768,557

Amounts in the table reflect the common stock equivalents of the noted instruments.

Comprehensive Income, Policy [Policy Text Block]

Comprehensive Loss

The Company has

items of comprehensive income or loss other than net loss.

New Accounting Pronouncements, Policy [Policy Text Block]

Recently Issued But

Not

Yet Adopted Accounting Pronouncements

August 2018,

the FASB issued ASU

2018

13,

Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurements,

which changes the fair value measurement disclosure requirements of ASC

820.

The goal of the ASU is to improve the effectiveness of ASC

820's

December 15, 2019

and interim periods within those years. The Company is currently evaluating the potential impact of the adoption of this standard on its related disclosures.

July 2017,

the FASB issued ASU

2017

11,

Earnings Per Share (Topic

260

); Distinguishing Liabilities from Equity (Topic

480

); Derivatives and Hedging (Topic

815

The

first

part of this update addresses the complexity of accounting for certain financial instruments with down round features and the

second

part addresses the complexity of distinguishing liabilities from equity. The guidance is applicable to public business entities for fiscal years beginning after

December 15, 2018

February 2016,

the FASB issued ASU

2016

02,

Leases (Topic

842

Under the new guidance

lessees are required to record a right-of-use (ROU) asset and a lease liability for all leases with a term greater than

months, measured on a discounted basis. Leases with a term of

months or less will be accounted for similar to existing guidance for operating leases. ASC

842

will be effective for the Company on

January 1, 2019,

and the Company expects to apply the practical expedients allowed by the standard, mainly related to the reassessment of expired or existing leases. See Note

$0.3

million to

$0.4

million upon adoption. Management does

not

expect a material impact to the Company’s Consolidated Statements of Operations or Consolidated Statements of Cash Flows.

Recently Adopted Accounting Pronouncements

January 2017,

the FASB issued ASU

2017

04,

Intangibles-Goodwill and Other (Topic

350

)

which simplifies the accounting for goodwill impairments by eliminating step

December 15, 2019,

including interim periods within such fiscal years. Early adoption is allowed for all entities as of

January 1, 2017,

for annual and any interim impairment tests occurring on or after

January 1, 2017.

The Company early adopted this standard in the

third

quarter of

2018.

See Note

for further discussion of the Company's intangible assets, including goodwill.

March

2016,

the FASB issued ASU

2016

09,

Compensation – Improvements to Employee Share-Based Payment Accounting

December 15, 2016

and interim periods within those years. The Company adopted this standard in

2017

by electing to account for forfeitures in the period that they occur. Under ASU

2016

09,

$1,000

January 1, 2017.

Note 3 - Basis of Presentation and Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2018

Notes Tables

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

	Year ended December 31,
	2018			2017
Basic net loss per common share calculation:
Net loss	$	(18,369,810	)	$	(1,364,518	)
Accretion of Series A cumulative preferred dividends		(85,993	)		(1,252,394	)
Deemed dividend related to the make-whole provision for the conversion of Series A convertible preferred stock into common stock		(8,167,895	)		—
Net loss attributable to common stockholders	$	(26,623,698	)	$	(2,616,912	)

Weighted average shares outstanding, basic		3,242,301			827,575
Net loss per share of common, basic	$	(8.21	)	$	(3.16	)
Diluted net loss per common share calculation:
Net loss attributable to common stockholders		(26,623,698	)		(2,616,912	)
Change in fair value of warrant liability		—			(22,072,322	)
Diluted net loss		(26,623,698	)		(24,689,234	)
Weighted average common shares outstanding, basic		3,242,301			827,575
Common stock equivalents arising from warrants		—			20,515
Common stock equivalents		3,242,301			848,090
Net loss per share of common stock, diluted	$	(8.21	)	$	(29.11	)

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]

	December 31,
	2018		2017
Convertible debt		—		14,292
Common stock warrants		2,087,012		29,848
Convertible preferred stock		—		553,752
Stock options		203,736		170,461
Unvested restricted stock awards		—		204
		2,290,748		768,557

Note 4 - Property and Equipment (Tables)

12 Months Ended

Dec. 31, 2018

Notes Tables

Property, Plant and Equipment [Table Text Block]

	December 31,
	2018			2017
Laboratory equipment	$	182,357		$	182,357
Furniture and office equipment		155,113			155,113
Leasehold improvements		430,000			430,000
Total property and equipment		767,470			767,470
Less: accumulated depreciation		(417,189	)		(306,818	)
Property and equipment, net	$	350,281		$	460,652

Note 6 - Accrued Expenses and Other Current Liabilities (Tables)

12 Months Ended

Dec. 31, 2018

Notes Tables

Other Current Liabilities [Table Text Block]

	December 31,
	2018		2017
Accrued interest payable	$	—	$	37,415
Accrued Series A convertible preferred stock dividends		—		1,062,314
Accrued payroll and payroll related expenses		409,889		312,221
Accrued professional fees		69,231		122,711
Accrued clinical studies expenses		34,000		63,350
Other		92,106		30,840
Total	$	605,226	$	1,628,851

Note 7 - Convertible Debt (Tables)

12 Months Ended

Dec. 31, 2018

Notes Tables

Convertible Debt [Table Text Block]

	December 31, 2017
Series B convertible notes		550,000
Less current portion		(550,000	)
Long-term debt, net of current portion	$	—

Note 8 - Commitments and Contingencies (Tables)

12 Months Ended

Dec. 31, 2018

Notes Tables

Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]

	Rental Commitments
2019	$	114,409
2020		116,464
2021		118,519
2022		39,735
Total	$	389,127

Note 9 - Convertible Preferred Stock, Stockholders' Equity and Common Stock Warrants (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Schedule of Warrants Outstanding to Acquire Shares of Common Stock [Table Text Block]	<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 56%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Outstanding</div></div></div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td colspan="6" rowspan="1" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 55%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Range of exercise</div></div></div></div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">price per share</div></div></div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="1" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 12%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Expiration</div></div></div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">dates</div></div></div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 56%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Common stock warrants issued prior to 2016</div> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,767</div></td> <td nowrap="nowrap" style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td colspan="4" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 5%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">$562.50</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 5%; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 5%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$735.00</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2019</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 56%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Common stock warrants issued in 2017 related to Series A convertible preferred stock offering</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">903,870</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td colspan="4" rowspan="1" style="width: 5%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td rowspan="1" style="width: 5%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$33.30</div></td> <td rowspan="1" style="width: 5%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="1" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 12%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">March 2022</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 56%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Common stock warrants issued in 2018 related to the common stock offering</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,181,375</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td colspan="4" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 5%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">$12.00</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 5%; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 5%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$15.00</div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="1" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 12%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">January 2023</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 56%;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,087,012</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td> <td colspan="4" rowspan="1" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 5%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td rowspan="1" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 5%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td rowspan="1" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 5%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 12%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> </table></div>

Note 10 - Stock-based Compensation (Tables)

12 Months Ended

Dec. 31, 2018

Notes Tables

Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]

	Year ended December 31,
	2018		2017
Research and development	$	62,161	$	674,643
General and administrative		1,159,430		716,425
Total stock-based compensation expense	$	1,221,591	$	1,391,068

Share-based Compensation, Stock Options, Activity [Table Text Block]

	Number of Options			Weighted average exercise price per share		Weighted average remaining contractual life (in years)		Aggregate Intrinsic Value
Balance at January 1, 2017		147,214		$	121.37
Granted		23,345			36.92
Expired		(98	)		225.00
Balance at January 1, 2018		170,461		$	109.74		7.13	$	4,746
Granted		44,005			15.37
Forfeited		(10,583	)		131.25
Expired		(147	)		256.50
Outstanding at December 31, 2018		203,736		$	88.14		6.70	$	143
Exercisable at December 31, 2018		167,585		$	101.69		6.25	$	143
Vested and expected to vest at December 31, 2018		203,736		$	88.14		6.70	$	143

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

	2018			2017
Expected term (in years)	5.27	—	5.66	5.27	—	6.00
Risk-free interest rate	2.3%	—	2.8%	1.8%	—	2.4%
Expected volatility	113.6%	—	115.0%	109.8%	—	136.7%
Dividend yield	—	—	—	—	—	—

Note 12 - Income Taxes (Tables)

12 Months Ended

Dec. 31, 2018

Notes Tables

Schedule of Deferred Tax Assets and Liabilities [Table Text Block]

Deferred tax assets	December 31, 2018			December 31, 2017
Net operating loss carryforwards	$	5,875,074		$	5,310,628
Stock option compensation		2,456,410			2,141,973
Orphan Drug credits		2,847,803			2,537,039
Capitalized start-up costs and other		7,349,092			5,247,468
Valuation allowance		(18,091,090	)		(15,237,108	)
Net deferred tax asset	$	437,289

Deferred tax liabilities
Intangible assets		(2,223,678	)		(2,223,678	)
Net deferred tax liability	$	(1,786,389	)	$	(2,223,678	)

Summary of Operating Loss Carryforwards [Table Text Block]

Combined NOL Carryforwards:	December 31, 2018
Federal	$	22,819,972
State		22,845,568

Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]

Rate reconciliation:	December 31, 2018			December 31, 2017
Federal tax benefit at statutory rate		(21.0	)%		(34.0	)%
State tax, net of Federal benefit		(2.9	)%		(16.3	)%
Change in fair value of warrant		—	%		(126.1	)%
Change in tax rate		—	%		205.5	%
Goodwill impairment		7.7	%		—	%
Orphan drug credit		(1.3	)%		(36.0	)%
Change in valuation allowance		15.2	%		(38.8	)%
Stock compensation		—	%		1.2	%
Other		—	%		1.0	%
Total provision		(2.3	)%		(43.5	)%

Note 13 - Fair Value Measurements (Tables)

12 Months Ended

Dec. 31, 2018

Notes Tables

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]

	Common Stock Warrant Liability
Balance at January 1, 2017	$	—
Issued in connection with the Series A convertible preferred stock		35,225,846
Change in fair value		(22,072,322	)
Reclassification of Series A warrants to additional paid in capital		(13,153,524	)
Balance at December 31, 2017	$	—

Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]

Stock price	$	21.60
Exercise price	$	33.30
Expected term (in years)		4.38
Risk-free interest rate		1.9	%
Expected volatility		104.1	%
Dividend yield		—

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

Note 1 - Organization and Description of Business (Details Textual)	Dec. 13, 2018
Reverse Stock Split [Member ]
Stockholders' Equity Note, Stock Split, Conversion Ratio	15

Note 2 - Liquidity (Details Textual) - USD ($) $ / shares in Units, $ in Thousands		1 Months Ended
	Jan. 22, 2018	Jan. 31, 2018	Dec. 31, 2018	Dec. 31, 2017
Common Stock, Par or Stated Value Per Share	$ 0.001		$ 0.001	$ 0.001
Conversion From Series A Preferred Stock to Common Stock [Member]
Conversion of Stock, Shares Issued	1,400,462	1,400,462
Warrants Issued in Connection with the January 2018 Offering [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	1,000,000	1,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 12	$ 12
Class of Warrant or Right, Term	5 years
Warrants Issued in Connection with the January 2018 Offering [Member] \| Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 15
Additional Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights		12
Underwriter Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 15	$ 15
Class of Warrant or Right, Term	5 years	5 years
Underwriter Warrants [Member] \| Maximum [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	50,000	50,000
January 2018 Offering [Member]
Stock Issued During Period, Shares, New Issues	1,000,000	1,000,000
Share Price	$ 12
Proceeds from Issuance or Sale of Equity, Total	$ 10,800	$ 10,800
January 2018 Offering [Member] \| Additional Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	131,375

Note 3 - Basis of Presentation and Summary of Significant Accounting Policies (Details Textual) - USD ($)
xbrli-pure in Thousands

3 Months Ended

12 Months Ended

Dec. 31, 2018

Sep. 30, 2018

Dec. 31, 2018

Dec. 31, 2017

Jan. 01, 2019

Jan. 01, 2017

Dec. 31, 2016

Impairment of Long-Lived Assets to be Disposed of

$ 0

Impairment of Intangible Assets (Excluding Goodwill), Total

Goodwill, Impairment Loss

$ 2,700,000

$ 4,200,000

$ 6,929,258

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate

0.00%

Assets, Total

18,201,992

$ 18,201,992

$ 26,145,815

Cumulative Effect of New Accounting Principle in Period of Adoption

^[1]

Liabilities, Total

$ 2,590,433

4,915,871

Additional Paid-in Capital [Member]

Cumulative Effect of New Accounting Principle in Period of Adoption

^[1]

$ 1,134

Accounting Standards Update 2016-09 [Member] | Additional Paid-in Capital [Member]

Cumulative Effect of New Accounting Principle in Period of Adoption

$ 1,000

Accounting Standards Update 2016-09 [Member] | AOCI Attributable to Parent [Member]

Cumulative Effect of New Accounting Principle in Period of Adoption

$ (1,000)

Minimum [Member]

Property, Plant and Equipment, Useful Life

2 years

Minimum [Member] | Accounting Standards Update 2016-02 [Member] | Subsequent Event [Member]

Assets, Total

$ 300,000

Liabilities, Total

300,000

Maximum [Member]

Property, Plant and Equipment, Useful Life

15 years

Maximum [Member] | Accounting Standards Update 2016-02 [Member] | Subsequent Event [Member]

Assets, Total

400,000

Liabilities, Total

$ 400,000

Fair Value, Inputs, Level 3 [Member] | Convertible Note, Series B [Member]

Convertible Debt, Fair Value Disclosures

$ 600,000

[1]	In 2017, the Company adopted provisions of ASU 2016-09, Improvements to Employee Share Based Payment Accounting, resulting in a cumulative effect adjustment to Accumulated Deficit and Additional Paid-in Capital for previously unrecognized stock-based compensation expense.

Note 3 - Basis of Presentation and Summary of Significant Accounting Policies - Basic and Diluted Earnings Per Share (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Basic net loss per common share calculation:
Net loss	$ (18,369,810)	$ (1,364,518)
Accretion of Series A cumulative preferred dividends	(85,993)	(1,252,394)
Deemed dividend related to the make-whole provision for the conversion of Series A convertible preferred stock into common stock	(8,167,895)
Net loss attributable to common stockholders	$ (26,623,698)	$ (2,616,912)
Weighted average shares outstanding, basic (in shares)	3,242,301	827,575
Net loss per share of common stock, basic (in dollars per share)	$ (8.21)	$ (3.16)
Diluted net loss per common share calculation:
Net loss attributable to common stockholders	$ (26,623,698)	$ (2,616,912)
Change in fair value of warrant liability		(22,072,322)
Diluted net loss	$ (26,623,698)	$ (24,689,234)
Weighted average shares outstanding, basic (in shares)	3,242,301	827,575
Common stock equivalents arising from warrants (in shares)		20,515
Common stock equivalents (in shares)	3,242,301	848,090
Net loss per share of common stock, diluted (in dollars per share)	$ (8.21)	$ (29.11)

Note 3 - Basis of Presentation and Summary of Significant Accounting Policies - Outstanding Dilutive Securities (Details) - shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Anti-dilutive securities (in shares)	2,290,748	768,557
Convertible Debt Securities [Member]
Anti-dilutive securities (in shares)		14,292
Warrant [Member]
Anti-dilutive securities (in shares)	2,087,012	29,848
Series A Convertible Preferred Stock [Member]
Anti-dilutive securities (in shares)		553,752
Employee Stock Option [Member]
Anti-dilutive securities (in shares)	203,736	170,461
Restricted Stock [Member]
Anti-dilutive securities (in shares)		204

Note 4 - Property and Equipment (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Depreciation, Total	$ 110,371	$ 67,981

Note 4 - Property and Equipment - Property and Equipment (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Property and equipment, gross	$ 767,470	$ 767,470
Less: accumulated depreciation	(417,189)	(306,818)
Property and equipment, net	350,281	460,652
Laboratory Equipment [Member]
Property and equipment, gross	182,357	182,357
Furniture and Fixtures [Member]
Property and equipment, gross	155,113	155,113
Leasehold Improvements [Member]
Property and equipment, gross	$ 430,000	$ 430,000

Note 5 - Goodwill and Intangible Assets (Details Textual) - USD ($)	3 Months Ended		12 Months Ended
	Dec. 31, 2018	Sep. 30, 2018	Dec. 31, 2018	Dec. 31, 2017
Goodwill, Impairment Loss	$ 2,700,000	$ 4,200,000	$ 6,929,258
Goodwill, Ending Balance	0		0	6,929,258
Impairment of Intangible Assets (Excluding Goodwill), Total			0	0
RES-529 [Member]
Intangible Assets, Gross (Excluding Goodwill), Total	$ 8,600,000		8,600,000	8,600,000
Impairment of Intangible Assets (Excluding Goodwill), Total			$ 0	$ 0

Note 6 - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Accrued interest payable		$ 37,415
Accrued Series A convertible preferred stock dividends		1,062,314
Accrued payroll and payroll related expenses	409,889	312,221
Accrued professional fees	69,231	122,711
Accrued clinical studies expenses	34,000	63,350
Other	92,106	30,840
Total	$ 605,226	$ 1,628,851

Note 7 - Convertible Debt (Details Textual) - USD ($)	3 Months Ended	12 Months Ended
Note 7 - Convertible Debt (Details Textual) - USD ($)	Jun. 30, 2018	Dec. 31, 2018	Dec. 31, 2017
Repayments of Convertible Debt		$ 550,000	$ 1,880,000
Interest Paid, Excluding Capitalized Interest, Operating Activities		40,142	112,800
Convertible Debt, Total		0
Interest Expense, Total		$ 3,000	100,000
Interest Payable			$ 37,000
Convertible Note, Series B [Member]
Repayments of Convertible Debt	$ 600,000
Interest Paid, Excluding Capitalized Interest, Operating Activities	$ 40,000

Note 7 - Convertible Debt - Outstanding Convertible Notes (Details)	Dec. 31, 2017 USD ($)
Series B convertible notes	$ 550,000
Less current portion	(550,000)
Long-term debt, net of current portion

Note 8 - Commitments and Contingencies (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Research and Development Expense, Total	$ 5,751,940	$ 5,088,621
Arrangement With Clinical Research Organization [Member]
Research and Development Expense, Total	1,600,000	1,000,000
Prepaid Research and Development Expense	800,000
Charlottesville, Virginia [Member] \| Building [Member]
Operating Leases, Rent Expense, Net, Total	$ 100,000	$ 100,000

Note 8 - Commitments and Contingencies - Total Future Operating Lease Obligations (Details)	Dec. 31, 2018 USD ($)
2019	$ 114,409
2020	116,464
2021	118,519
2022	39,735
Total	$ 389,127

Note 9 - Convertible Preferred Stock, Stockholders' Equity and Common Stock Warrants (Details Textual) - USD ($)		1 Months Ended		12 Months Ended
	Jan. 22, 2018	Jan. 31, 2018	Mar. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Mar. 13, 2017
Stock Issued During Period, Shares, Issued for Services				7,792	1,174
Stock Issued During Period, Shares, Conversion of Convertible Securities		553,752
Common Stock Dividends, Shares		68,815
Stock Issued During Period, Shares, Make-whole Adjustment		777,895
Dividends, Make-whole Adjustment		$ 8,200,000		$ 8,167,895
Proceeds from Issuance of Convertible Preferred Stock, Net of Offering Costs					22,129,774
Warrant Expense					$ 10,225,846
Stock Repurchased and Retired During Period, Shares				0	0
Class of Warrant or Rights, Expired				28,123	867
Series A Preferred Stock [Member]
Proceeds from Issuance of Private Placement					$ 0
Preferred Stock, Shares Authorized				0		13,750,000
Preferred Stock, Shares Issued, Total				0
Preferred Stock, Shares Outstanding, Ending Balance				0
Conversion From Series A Preferred Stock to Common Stock [Member]
Conversion of Stock, Shares Issued	1,400,462	1,400,462
Warrants Issued in Connection with the January 2018 Offering [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	1,000,000	1,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 12	$ 12
Class of Warrant or Right, Term	5 years
Warrants Issued in Connection with the January 2018 Offering [Member] \| Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 15
Option Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		150,000
Additional Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 12
Class of Warrant or Right, Granted		131,375
Underwriter Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 15	$ 15
Class of Warrant or Right, Term	5 years	5 years
Underwriter Warrants [Member] \| Maximum [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	50,000	50,000
January 2018 Offering [Member]
Stock Issued During Period, Shares, New Issues	1,000,000	1,000,000
Proceeds from Issuance or Sale of Equity, Total	$ 10,800,000	$ 10,800,000
Stock Issued During Period, Shares, Issued for Services		150,000
January 2018 Offering [Member] \| Additional Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	131,375
Private Placement [Member] \| Warrant [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 33.30
Class of Warrant or Right, Term			5 years
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right			1
Warrant Expense					$ 10,200,000
Private Placement [Member] \| Series A Preferred Stock [Member]
Proceeds from Issuance of Private Placement			$ 25,000,000
Number of Convertible Preferred Stock Per Unit			1
Preferred Stock, Dividend Rate, Percentage			8.00%
Number of Common Stock Per Unit			1
Convertible Preferred Stock, Conversion Price			$ 30.30
Temporary Equity, Stock Issued During Period, New Issues			12,376,329
Proceeds from Issuance of Convertible Preferred Stock, Net of Offering Costs			$ 22,100,000
Payments of Stock Issuance Costs			$ 2,900,000
Private Placement [Member] \| Series B Preferred Stock [Member] \| Placement Agent [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 33.30
Class of Warrant or Right, Term			5 years
Class of Warrant or Right, Granted During Period			78,637

Note 9 - Convertible Preferred Stock, Stockholders' Equity and Common Stock Warrants - Warrants Outstanding to Acquire Shares of Its Common Stock (Details) - $ / shares	Dec. 31, 2018	Jan. 31, 2018	Jan. 22, 2018
Common stock warrants, outstanding (in shares)	2,087,012
Warrants issued before 2016 [Member]
Common stock warrants, outstanding (in shares)	1,767
Warrants issued before 2016 [Member] \| Minimum [Member]
Range of exercise price (in dollars per share)	$ 562.50
Warrants issued before 2016 [Member] \| Maximum [Member]
Range of exercise price (in dollars per share)	$ 735
Warrants Attached to Series A Convertible Preferred Stock [Member]
Common stock warrants, outstanding (in shares)	903,870
Range of exercise price (in dollars per share)	$ 33.30
Warrants Issued in Connection with the January 2018 Offering [Member]
Common stock warrants, outstanding (in shares)	1,181,375
Range of exercise price (in dollars per share)		$ 12	$ 12
Warrants Issued in Connection with the January 2018 Offering [Member] \| Minimum [Member]
Range of exercise price (in dollars per share)	$ 12
Warrants Issued in Connection with the January 2018 Offering [Member] \| Maximum [Member]
Range of exercise price (in dollars per share)	$ 15

Note 10 - Stock-based Compensation (Details Textual) - USD ($)			12 Months Ended
	Jan. 01, 2019	Jul. 01, 2016	Dec. 31, 2018	Dec. 31, 2017	Jul. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross			44,005	23,345
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period			0
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period			10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value			$ 1,200,000	$ 1,100,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total			$ 600,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition			1 year 146 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value			$ 12.63	$ 30.43
Employee Stock Option [Member] \| Vest Monthly [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period			3 years
Non-employee Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross			0	626
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value			$ 4,000	$ 90,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total			$ 1,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares, Ending Balance			219
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition			1 year 58 days
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance			0
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period			204	409
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value			$ 6,000	$ 12,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period			0	0
Equity Incentive Plan 2015 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized					33,333
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant					1,814
Percentage of Total Shares Eligible for Plan Reserve, On an Annual Basis		4.00%
Equity Incentive Plan 2015 [Member] \| Subsequent Event [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized	135,049

Note 10 - Stock-based Compensation - Stock-based Compensation Expense (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Stock-based compensation expense	$ 1,221,591	$ 1,391,068
Research and Development Expense [Member]
Stock-based compensation expense	62,161	674,643
General and Administrative Expense [Member]
Stock-based compensation expense	$ 1,159,430	$ 716,425

Note 10 - Stock-based Compensation - Stock Option Activity (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Options outstanding, number (in shares)	170,461	147,214
Options outstanding, weighted-average exercise price (in dollars per share)	$ 109.74	$ 121.37
Granted (in shares)	44,005	23,345
Granted, weighted-average exercise price (in dollars per share)	$ 15.37	$ 36.92
Expired (in shares)	(147)	(98)
Expired, weighted-average exercise price (in dollars per share)	$ 256.50	$ 225
Options outstanding, weighted-average remaining contractual life (Year)	6 years 255 days	7 years 47 days
Options outstanding, aggregate intrinsic value	$ 143	$ 4,746
Forfeited (in shares)	(10,583)
Forfeited, weighted-average exercise price (in dollars per share)	$ 131.25
Options outstanding, number (in shares)	203,736	170,461
Options outstanding, weighted-average exercise price (in dollars per share)	$ 88.14	$ 109.74
Exercisable (in shares)	167,585
Exercisable, weighted-average exercise price (in dollars per share)	$ 101.69
Exercisable, weighted-average remaining contractual life (Year)	6 years 91 days
Exercisable, aggregate intrinsic value	$ 143
Vested and expected to vest (in shares)	203,736
Vested and expected to vest, weighted-average exercise price (in dollars per share)	$ 88.14
Vested and expected to vest, weighted-average remaining contractual life (Year)	6 years 255 days
Vested and expected to vest, aggregate intrinsic value	$ 143

Note 10 - Stock-based Compensation - Fair Value Assumptions (Details)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Dividend yield	0.00%
Minimum [Member]
Expected term (Year)	5 years 98 days	5 years 98 days
Risk-free interest rate	2.30%	1.80%
Expected volatility	113.60%	109.80%
Maximum [Member]
Expected term (Year)	5 years 240 days	6 years
Risk-free interest rate	2.80%	2.40%
Expected volatility	115.00%	136.70%

Note 11 - Defined Contribution Retirement Plan (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent	90.00%
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay	4.00%
Defined Contribution Plan, Employer Discretionary Contribution Amount	$ 68,000	$ 49,000

Note 12 - Income Taxes (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Unrecognized Tax Benefits, Ending Balance	$ 0	$ 0
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	21.00%	34.00%
Income Tax Expense (Benefit), Continuing Operations, Adjustment of Deferred Tax (Asset) Liability	$ (400)	$ (1,100)

Note 12 - Income Taxes - Deferred Tax Assets and Liabilities (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Net operating loss carryforwards	$ 5,875,074	$ 5,310,628
Stock option compensation	2,456,410	2,141,973
Orphan Drug credits	2,847,803	2,537,039
Capitalized start-up costs and other	7,349,092	5,247,468
Valuation allowance	(18,091,090)	(15,237,108)
Net deferred tax asset	437,289
Intangible assets	(2,223,678)	(2,223,678)
Net deferred tax liability	$ (1,786,389)	$ (2,223,678)

Note 12 - Income Taxes - Operating Loss Carryforwards (Details)	Dec. 31, 2018 USD ($)
Domestic Tax Authority [Member]
Operating loss carryforwards	$ 22,819,972
State and Local Jurisdiction [Member]
Operating loss carryforwards	$ 22,845,568

Note 12 - Income Taxes - Reconciliation of Income Tax Rate (Details)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Federal tax benefit at statutory rate	(21.00%)	(34.00%)
State tax, net of Federal benefit	(2.90%)	(16.30%)
Change in fair value of warrant		(126.10%)
Change in tax rate		205.50%
Goodwill impairment	7.70%
Orphan drug credit	(1.30%)	(36.00%)
Change in valuation allowance	15.20%	(38.80%)
Stock compensation		1.20%
Other		1.00%
Total provision	(2.30%)	(43.50%)

Note 13 - Fair Value Measurements - Reconciliation of Common Stock Warrant Liability (Details) - Contingent Consideration [Member]	12 Months Ended
	Dec. 31, 2017 USD ($)
Balance
Issued in connection with the Series A convertible preferred stock	35,225,846
Change in fair value	(22,072,322)
Reclassification of Series A warrants to additional paid in capital	(13,153,524)
Balance

Note 13 - Fair Value Measurements - Black-Scholes Model and Assumptions (Details)	Nov. 01, 2017
Measurement Input, Share Price [Member]
Stock price	21.6
Measurement Input, Exercise Price [Member]
Stock price	33.3
Measurement Input, Expected Term [Member]
Stock price	4.38
Measurement Input, Risk Free Interest Rate [Member]
Stock price	0.019
Measurement Input, Price Volatility [Member]
Stock price	1.041
Measurement Input, Expected Dividend Rate [Member]
Stock price